RVU-120 is under clinical development by Ryvu Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RVU-120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RVU-120 overview

RVU-120 is under development for the treatment of hematological tumors, triple negative breast cancer, myeloproliferative disorders, lymphomas including primary or secondary myelofibrosis, solid tumors, relapsed/refractory acute myeloid leukemia, diffuse large B-cell lymphoma, polycythemia vera, anemia and myelodysplastic syndrome. The drug candidate is administered through oral route. It acts by targeting Cyclin Dependent Kinase 19 and Cyclin Dependent Kinase 8.
It was also under development for the treatment of mantle cell lymphoma, colorectal cancer, acute lymphatic leukemia, breast cancer, Wilms’ tumors(nephroblastoma), congenital hypoblastic anemia, non-Hodgkin's lymphoma, myleoproliferatory disorder and prostate cancer.

Ryvu Therapeutics overview

Ryvu Therapeutics is a biopharmaceutical company that specializes in the discovery and development of novel small-molecule therapies in the area of oncology. The company is headquartered in Krakow, Lesser Poland, Poland.

For a complete picture of RVU-120’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.